Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.

@article{Cheema2011EnhancedAE,
  title={Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts.},
  author={Tooba A. Cheema and Ryuichi Kanai and Geon Woo Kim and Hiroaki Wakimoto and Brent J. Passer and Samuel David Rabkin and Robert L. Martuza},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 23},
  pages={7383-93}
}
PURPOSE Glioblastoma (GBM) inevitably recurs despite surgery, radiation, and chemotherapy. A subpopulation of tumor cells, GBM stem cells (GSC), has been implicated in this recurrence. The chemotherapeutic agent etoposide is generally reserved for treating recurrent tumors; however, its effectiveness is limited due to acute and cumulative toxicities to normal tissues. We investigate a novel combinatorial approach of low-dose etoposide with an oncolytic HSV to enhance antitumor activity and… CONTINUE READING
23 Citations
52 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive glioblastoma [monograph on the Internet

  • Y. Ino
  • [cited 2011 Sept 20]
  • 2011
1 Excerpt

Similar Papers

Loading similar papers…